Literature DB >> 8558135

Sentinel lesions of primary CNS lymphoma.

L Alderson1, M R Fetell, M Sisti, F Hochberg, M Cohen, D N Louis.   

Abstract

Some patients ultimately diagnosed with primary CNS lymphoma (PCNSL) have transient symptomatic contrast enhancing lesions. These "sentinel lesions" of PCNSL recede spontaneously or with corticosteroid treatment and present an important diagnostic dilemma because they show variable, but non-diagnostic histopathological features. Four previously healthy, immunocompetent patients aged 49 to 58 years had contrast enhancing intraparenchymal brain lesions. Before biopsy, three of the four were treated with corticosteroids. Initial biopsies showed demyelination with axonal sparing in two, non-specific inflammation in one, and normal brain in one. Infiltrating lymphocytes predominantly expressed T cell markers with rare B cells. All four patients recovered within two to four weeks after the initial biopsy and imaging studies showed resolution of the lesions. The CSF was normal in three of the four patients tested; oligoclonal bands were absent in both of the two tested. After seven to 11 months, each patient developed new symptomatic lesions in a different region of the brain, biopsy of which showed a B cell PCNSL. The mechanism of spontaneous involution of sentinel lesions is not understood, but may represent host immunity against the tumour. Sentinel lesions of PCNSL should be considered in patients with contrast enhancing focal parenchymal lesions that show non-specific or demyelinative histopathological changes. Close clinical and radiographic follow up is essential if PCNSL is to be diagnosed early in such patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558135      PMCID: PMC486201          DOI: 10.1136/jnnp.60.1.102

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  12 in total

1.  Primary central nervous system lymphoma imitates multiple sclerosis.

Authors:  L M DeAngelis
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

2.  Autopsy report of primary CNS B-cell lymphoma indistinguishable from multiple sclerosis: diagnosis with the immunoglobulin gene rearrangements analysis.

Authors:  Y Kuroda; T Kawasaki; S Haraoka; F Fujiyama; R Kakigi; M Abe; K Tabuchi; T Kuroiwa; T Kishikawa; H Sugihara
Journal:  J Neurol Sci       Date:  1992-09       Impact factor: 3.181

3.  Primary CNS lymphoma presenting as multiple sclerosis. A case study.

Authors:  G P Bender; R T Schapiro
Journal:  Minn Med       Date:  1989-03

4.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

5.  Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients.

Authors:  J J Kepes
Journal:  Ann Neurol       Date:  1993-01       Impact factor: 10.422

6.  Clinical and radiologic remission in reticulum cell sarcoma of the brain.

Authors:  R S Williams; R M Crowell; C M Fisher; K Davis; M H Lavyne; A H Ropper; A M Bremer
Journal:  Arch Neurol       Date:  1979-04

7.  Increasing incidence of primary brain lymphoma in the US.

Authors:  N L Eby; S Grufferman; C M Flannelly; S C Schold; F S Vogel; P C Burger
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

8.  Cancer dormancy: isolation and characterization of dormant lymphoma cells.

Authors:  E Yefenof; L J Picker; R H Scheuermann; T F Tucker; E S Vitetta; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies.

Authors:  T Meeker; J Lowder; M L Cleary; S Stewart; R Warnke; J Sklar; R Levy
Journal:  N Engl J Med       Date:  1985-06-27       Impact factor: 91.245

10.  Spontaneous regression of intracerebral lymphoma.

Authors:  K L Weingarten; R D Zimmerman; N E Leeds
Journal:  Radiology       Date:  1983-12       Impact factor: 11.105

View more
  21 in total

1.  Transient infundibular mass associated with temporary functional deficiency.

Authors:  Duncan Browne; Mary Armitage; Jeremy Small; Peter Lees
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

2.  Anti-Ma2 antibodies in B-cell primary CNS lymphoma.

Authors:  Markus Kraemer; Peter Berlit
Journal:  J Neurol       Date:  2007-04-10       Impact factor: 4.849

Review 3.  Classification, pathogenesis and molecular pathology of primary CNS lymphomas.

Authors:  W Paulus
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 4.  Primary central nervous system lymphoma: from clinical presentation to diagnosis.

Authors:  U Herrlinger; M Schabet; M Bitzer; D Petersen; P Krauseneck
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

5.  High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.

Authors:  Philipp Kiewe; Christoph Loddenkemper; Ioannis Anagnostopoulos; Mark Reinwald; Eckhard Thiel; Agnieszka Korfel
Journal:  Neuro Oncol       Date:  2007-02-14       Impact factor: 12.300

6.  Primary brain lymphomas after kidney transplantation: an under-recognized problem?

Authors:  Nuria Sola-Valls; Néstor Yesid Rodríguez C; Carola Arcal; Carlos Duran; Federico Oppenheimer; Teresa Ribalta; Armando Lopez-Guillermo; Josep Marí Campistol; Francesc Graus; Fritz Diekmann
Journal:  J Nephrol       Date:  2014-01-28       Impact factor: 3.902

7.  The development of primary central nervous system B-cell lymphoma in multiple sclerosis.

Authors:  Mark K Lyons; Orland K Boucher; Barry D Birch; Naresh P Patel
Journal:  Neurohospitalist       Date:  2011-07

8.  Pituitary gland involvement by a gamma delta hepatosplenic lymphoma, a mimicker of pituitary adenoma: report of a rare case.

Authors:  D Jain; M C Sharma; C Sarkar; V Suri; A Garg; A K Mahapatra; L Kumar
Journal:  J Neurooncol       Date:  2008-06       Impact factor: 4.130

9.  White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.

Authors:  Fayez Estephan; Xiaobu Ye; Omar Dzaye; Nina Wagner-Johnston; Lode Swinnen; Douglas E Gladstone; Rich Ambinder; David Olayinka Kamson; Sebastian Lambrecht; Stuart A Grossman; Doris D M Lin; Matthias Holdhoff
Journal:  J Neurooncol       Date:  2019-10-16       Impact factor: 4.130

Review 10.  Primary CNS lymphoma initially diagnosed as vasculitis.

Authors:  Lauren Feldman; Yuebing Li; Daniel Ontaneda
Journal:  Neurol Clin Pract       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.